Serotonin as a Mitogen in the Gastrointestinal Tract: Revisiting a Familiar Molecule in a New Role

Pooja A. Shah,1 Christine J. Park,1 Matthew P. Shaughnessy,1 and Robert A. Cowles1

1Division of Pediatric Surgery, Department of Surgery, Yale School of Medicine, New Haven, Connecticut

SUMMARY

Binding of serotonin receptors on intestinal epithelial cells and enteric neurons activates intracellular proliferative pathways. Potentiation of serotonin signaling has been linked to mucosal proliferation, enteric neurogenesis in the setting of intestinal injury, and the pathogenesis of colon cancer.

Serotonin signaling is ubiquitous in the gastrointestinal (GI) system, where it acts as a neurotransmitter in the enteric nervous system (ENS) and influences intestinal motility and inflammation. Since its discovery, serotonin has been linked to cellular proliferation in several types of tissues, including vascular smooth muscle, neurons, and hepatocytes. Activation of serotonin receptors on distinct cell types has been shown to induce well-known intracellular proliferation pathways. In the GI tract, potentiation of serotonin signaling results in enhanced intestinal epithelial proliferation, and decreased injury from intestinal inflammation. Furthermore, activation of the type 4 serotonin receptor on enteric neurons leads to neurogenesis and neuroprotection in the setting of intestinal injury. It is not surprising that the mitogenic properties of serotonin are pronounced within the GI tract, where enterochromaffin cells in the intestinal epithelium produce 90% of the body’s serotonin; however, these proliferative effects are attributed to increased serotonin signaling within the ENS compartment as opposed to the intestinal mucosa, which are functionally and chemically separate by virtue of the distinct tryptophan hydroxylase enzyme isoforms involved in serotonin synthesis. The exact mechanism by which serotonergic neurons in the ENS lead to intestinal proliferation are not known, but the activation of muscarinic receptors on intestinal crypt cells indicate that cholinergic signaling is essential to this signaling pathway. Further understanding of serotonin’s role in mucosal and enteric nervous system mitogenesis may aid in harnessing serotonin signaling for therapeutic benefit in many GI diseases, including inflammatory bowel disease, malabsorptive conditions, and cancer. (Cell Mol Gastroenterol Hepatol 2021;12:1093–1104; https://doi.org/10.1016/j.jcmgh.2021.05.008)

Keywords: Mitogenesis; Intestinal Epithelium; Enteric Nervous System.

Serotonin has long been viewed as a critical signaling molecule for gastrointestinal (GI) health, with a well-established role in GI motility and inflammation.1,2 More recently, serotonin has come into focus for its mitogenic properties in the intestine, both physiologic and pathologic. Cellular proliferation has been linked to serotonin signaling in myriad cell types and organ systems.3–5 This effect is illustrated uniquely in the intestine as a result of the juxtaposition between serotonin signaling in the gut epithelium, which produces a majority of the body’s serotonin supply, and within the enteric nervous system.

In this review, we synthesize contemporary understanding of serotonin signaling as it relates to cellular proliferation in the intestine. Specifically, we describe the serotonin receptor–initiated pathways involved in intestinal epithelial proliferation, enteric neurogenesis, and intestinal neoplasia. Although further research is necessary to harness the translational potential of serotonin-mediated proliferation in the intestinal mucosa and enteric nervous system, the therapeutic promise of this effect is substantial. Chronic conditions of intestinal injury and insufficiency, for example, in patients with inflammatory bowel disease or short-bowel syndrome, are costly and difficult to treat because of the limitations of intestinal replacement therapies.6 Induction of intestinal mucosal proliferation through the modulation of serotonin signaling is already within the means of medicine, given the established arsenal of serotonin transporter (SERT) inhibitors and serotonin-receptor antagonists that exist, and offers a new therapeutic prospect for this clinical problem.

Historical Perspective

Serotonin, named for the location in which it was first discovered (Latin serum) and one of its earliest known functions (Greek tonic), has a storied scientific history. Initial reports of the substance later identified as serotonin date back to 1868, when Ludvig and Schmidt7 observed that perfusion of dog muscle with defibrinogenated blood resulted in vasoconstriction. In the following decades, other investigators proposed that epinephrine was the responsible

**Abbreviations used in this paper:** 5-HT, 5-hydroxytryptamine (serotonin); 5-HTR, serotonin receptor; CNS, central nervous system; EC, enterochromaffin; ENS, enteric nervous system; GI, gastrointestinal; MAPK, mitogen-activated protein kinase; SERT, serotonin transporter; SSRI, serotonin reuptake inhibitor; TPH, tryptophan hydroxylase.

© 2021 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 2392-345X

https://doi.org/10.1016/j.jcmgh.2021.05.008
It was not until O’Connor observed that a substance stored in platelets exerted a vasoconstrictive effect on the intestine that a molecule distinct from epinephrine, which relaxes intestinal smooth muscle, was hypothesized to exist. The third and fourth decades of the 20th century saw substantial advancements in the understanding of serotonin physiology. Rapport et al are credited with isolating serotonin from blood and describing its structure as 5-hydroxytryptamine (5-HT) in 1948. However, it subsequently became clear that 5-HT was identical to the substance enteramine, which the Italian scientists Erspamer, Aspero, and Vialli had identified a decade earlier. Erspamer had selected this term to reflect the molecule’s site of production, in enterochromaffin (EC) cells in the gut mucosa, and contractile effect on intestinal smooth muscle. Discovery of serotonin’s excitatory neurotransmitter function originated in the hard-shell clam in 1953, which led soon thereafter to the identification of serotonergic cells in the vertebrate brain. Although the name serotonin has endured, the historical significance of enteramine has been realized as subsequent research showed the varied role of 5-HT in GI function, which we describe later.

**Overview of Serotonin Physiology**

Serotonin, or 5-HT, is a ubiquitous signaling molecule that has been ascribed diverse functions, including neurotransmission, vascular tone, hemostasis, bone resorption, GI function, and cellular proliferation. 5-HT is derived from the amino acid tryptophan in a 2-step enzymatic process involving tryptophan hydroxylase (TPH), followed by L-amino acid decarboxylase. TPH exists in 2 distinct isotypes in vertebrates: TPH1 is expressed in several non-neuronal cell types, most abundantly in the intestine, pineal gland, and pituitary gland, whereas TPH2 is expressed in serotonergic neurons in the central and enteric nervous systems (Figure 1). L-amino acid decarboxylase is an abundant and fast-acting enzyme that also is involved in...
catecholamine synthesis. As such, TPH is the rate-limiting step for 5-HT synthesis in peripheral tissues where tryptophan is readily available; in the central nervous system (CNS), 5-HT synthesis is rate-limited by transport of tryptophan across the blood-brain barrier.26 5-HT also is unable to cross the blood-brain barrier, thus lending spatial and functional separation based on where biosynthesis occurs.

Irrespective of where it is synthesized, serotonin exerts biologic action by binding to cell membrane–bound serotonin receptors (5-HTR). Numerous 5-HTR genes have been identified, each with the potential to produce distinct splice variants and isoforms of the final receptor protein. To date, 18 unique serotonin receptors have been identified and grouped into 7 families (5-HTR 1 through 5-HTR 7 ) on the basis of genetic homology and associated second messenger systems (Table 1).25 All 5-HTR subtypes are G-protein–coupled receptors with the exception of the 5-HTR 3 family, which are ligand-gated ion channels.26

Tight regulation of serotonin signaling is achieved by rapid intracellular reuptake of 5-HT by SERT on cell membranes. SERT is a sodium-dependent monoamine transporter protein responsible for removing free serotonin from the extracellular space, thus terminating the downstream effects of 5-HTR activation. Once within the cell, 5-HT can be degraded by a number of mechanisms. The most common pathway for serotonin catabolism involves the activity of monoamine oxidases A and B that produce the renally excreted metabolite 5-hydroxyindoleacetic acid.27

**Serotonin Production and Receptor Activation in the Intestine**

More than 90% of the body's serotonin is produced by TPH1 in EC cells in the mucosa of the small intestine. From here, it either acts in a paracrine fashion on the intestinal epithelium or enters portal circulation where it subsequently is stored in circulating platelets.28–30 Enteroendocrine cells are encountered throughout the epithelium of the GI tract from the stomach to the rectum, and produce hormones involved in several GI functions including digestion and motility.11 5-HT–producing EC cells comprise the largest subset of enteroendocrine cells, and are present along the length of the crypt–villus axis.32 Recent profiling of enteroendocrine cells in the gut have shown significant overlap between hormones secreted by cells that once were thought to be distinct subtypes.33 EC cells, for example, produce substance P and tachykinin in addition to 5-HT.32 The nearby enteric nervous system (ENS), termed the local nervous system for its ability to function without CNS input, contains serotonin-producing neurons in both a submucosal plexus that controls mucosal secretions and blood flow and a myenteric plexus that regulates motility. Similar to serotonergic neurons in the CNS, ENS neurons produce serotonin through the TPH2 enzymatic pathway.28,34

The specific paracrine effects of 5-HT within the gastrointestinal tract are determined by the distribution and location of various 5-HTRs. Receptors from the 5-HT 1 , 5-HT 2 , 5-HT 3 , 5-HT 4 , and 5-HT 7 receptor families have been identified in the intestine, with variable expression in the epithelium, ENS, and intestinal smooth muscle (reviewed by Mawe and Hoffman 35 ). The 5-HTR 4 and 5-HTR 2A have been localized to the intestinal epithelium.36,37 Although the exact position of the 5-HT 4 receptor along the crypt–villus axis has not been described definitively, there is convincing evidence that proliferative cells within the intestinal crypt are the targets of 5-HT 4 signaling effects.38 5-HTR 2A expression is most prominent in Paneth cells within the intestinal crypt.

---

**Table 1. Distribution of Serotonin Receptors on Cells Showing Serotonin-Induced Proliferation**

| Receptor | Cell type – signaling pathway (if known) | Reference |
|----------|-----------------------------------------|-----------|
| 5-HT 1A  | Neurons, Prostate cancer: MAPK/ERK, PI3K/Akt | Segi-Nishida, 2017 62 Dizey et al, 2011 116 |
| 5-HT 1B  | Pulmonary artery smooth muscle cells: ERK1/2, PDK | Liu et al, 2013 65 |
| 5-HT 1D  | Intestinal epithelium: WNT/β-catenin | Sui et al, 2015 108 |
| 5-HT 2A  | Pulmonary artery fibroblasts: p38 MAPK | Welsh et al, 2004 81 Balasubramanian and Paulose, 1998; Lesurtel et al, 2006 4 Launay et al, 1996 40 |
| 5-HT 2B  | Neuronal crest cells, Myocardial precursor cells, Fibroblast: MAPK/cyclin D1, MAPK/cyclin E | Choi et al, 1997 86 Choi et al, 1997 88 Nebigil et al, 2000 79 |
| 5-HT 2C  | Intestinal epithelium, Enteric neurons | Balasubramanian and Paulose, 1998; Lesurtel et al, 2006 4 |
| 5-HT 3   | Neurons in hippocampus, Intestinal epithelium, Enteric neurons | Segi-Nishida 2017 62 Pauwelyn and Lefebvre, 2017 70 Liu et al, 2009 67 Norum et al, 2003 78 Henriksen et al, 2012 77 |
| 5-HT 4   | Ovarian tumor cells | Choi et al, 1997 98 |
| 5-HT 7   | Osteosarcoma: p38 MAPK, ERK2 | Ballou et al, 2018 114 |

**Note.** Italics indicate neoplastic cell types. ERK, extracellular-signal-regulated kinase; PDK, pyruvate dehydrogenase kinase; PI3K, phosphoinositide-3 kinase.
Although our focus is on the mitogenic properties of serotonin, 5-HTR binding is essential for multiple intestinal functions. First, 5-HT mediates the inflammatory response in the intestinal mucosa. Animal models have shown that potentiation of serotonin signaling, either through pharmacologic inhibition or genetic modification, results in more severe colitis and increased levels of proinflammatory cytokines in the intestinal mucosa. Proliferation of EC cells from intestinal epithelial progenitors is under immunologic control; specifically, an intact mucosal immune response, including the recruitment of CD3+ and CD4+ T lymphocytes and production of interleukin 13, is necessary for EC cell hyperplasia and consequent enhanced mucosal 5-HT production seen in states of enteric infection and inflammation.40–43 Inflammatory states also result in down-regulation of SERT, further potentiating 5-HT signaling.44 Conversely, depletion of serotonin, modeled with TPH1 knockout mice, is protective against mucosal inflammation.45 Interestingly, TPH2 knockout mice showed more severe colitis than wild-type littermates, suggesting an anti-inflammatory role of serotonin signaling in the ENS.46,47 5-HTR7 on enteric neurons and intestinal myeloid cells and 5-HTR1ß on lymphocytes are the specific serotonin receptors activated during intestinal inflammation; although contrary to what one would expect, 5-HTR7 binding appears to confer an anti-inflammatory effect.2,47–49

Second, the peristaltic reflex, or the intrinsic propulsive motility of the intestine, is regulated by mucosal serotonin.50,51 Animal studies have shown prolonged gastric transit in Tph1–/– mice and mice treated with 5-HTR antagonists.19,50 This prokinetic effect is apparent in carcinoid syndrome, in which EC cell proliferation and the consequent increase in serotonin production manifests with symptoms of hypermotility and diarrhea.52 Neuronal 5-HT produced in the ENS has an apparent inhibitory effect on gastric emptying, but its role is more subtle than that of mucosal 5-HT in overall gut motility.50

The 5-HTR3 subtype warrants particular attention for its role in gut motility. In the myenteric plexus, 5-HTR3 activation is involved in initiating the peristaltic reflex and antagonism of this receptor opposes carcinoid-associated diarrhea.53 Inhibition of 5-HTR3 also has a potent anti-emetic effect, as shown by the 5-HTR3 antagonist ondansetron, which is used to treat chemotherapy-induced nausea and vomiting. This pharmacologic effect is mediated by competitive inhibition of 5-HTR3 on visceral afferent neurons and neurons in the vomiting center of the brainstem, as well as by inhibition of 5-HT production by EC cells.54,55

Serotonin-Mediated Growth of the Intestinal Epithelium

Evidence linking intestinal epithelial proliferation to serotonergic regulation was presented by Tutton and Barkla in the 1970s, who showed that serotonin blockade was associated with inhibition of colonic adenocarcinoma cell division in rats. Later, Gross et al. showed that serotonin signaling enhances proliferation of non-neoplastic epithelial cells. Maintenance of the intestinal mucosal epithelium is achieved via a balance between cell production and cell death. Multipotent intestinal stem cells at the base of epithelial crypts proliferate and give rise to all epithelial cell types, including absorptive enterocytes, Paneth cells, goblet cells, and EC cells. Epithelial cell apoptosis and extrusion into the intestinal lumen, a process known as shedding, occurs at the tips of intestinal villi.58 Alterations in the fine regulation of these processes underlie phenotypic changes seen in the mucosal response to injury, adaptation after bowel resection, and the development of intestinal neoplasia.59 The findings by Gross, and others subsequently, showed that serotonin potentiation in mice modulated this intestinal homeostasis, leading to increased crypt cell proliferation, elongation of intestinal villi and crypts, and overall expansion of mucosal surface area in the small intestine.60 Interestingly, epithelial proliferation is linked specifically to the activity of neuronal serotonin, or 5-HT synthesized by TPH2; in contrast, the depletion of EC cell–produced 5-HT in experiments with TPH1 knockout mice did not alter mucosal proliferation.5

Furthermore, the absorptive function of the intestine is enhanced in animals with potentiated serotonin signaling, correlating with the observed increase in mucosal surface area.61–63 This change in absorptive capacity does not reflect an increased proportion of absorptive enterocytes in villi. The fact that the cellular composition of the epithelium is not altered in these animals suggests that cellular division is induced in stem cells at the base of the intestinal crypt, or in the adjacent undifferentiated transit-amplifying cells.51

5-HT–mediated control over crypt cell division has also been observed in studies of intestinal injury. In animal models of intestinal ischemia and reperfusion, mice with enhanced serotonin signaling showed less severe mucosal injury and increased enterocyte proliferation after injury compared with control animals.45,64 In addition, patients with inflammatory bowel disease show deficiencies in mucosal 5-HT signaling, including decreased EC cell populations in the intestinal epithelium.65 Together, these findings have therapeutic implications for malabsorptive conditions such as short-bowel syndrome, and bowel injury more broadly, which warrants further investigation.

Serotonin Receptors in the Intestinal Epithelium

Compelling evidence that serotonin stimulates mitogenic pathways in the intestinal epithelium has led to efforts to characterize the signaling pathways responsible for these effects, starting with identification of the specific 5-HT receptors present on intestinal villi and on proliferative cells within the intestinal crypt. The 5-HTR4 subtype has been localized to the intestinal epithelium throughout the small intestine and colon, and also is expressed in the ENS and on intestinal smooth muscle cells. The proliferative expression of 5-HTR4 in different cellular compartments contributes to its role in enteric neuroprotection, intestinal inflammation, and motility.50,66–69

There is substantial evidence of the intersection between serotonergic and cholinergic signaling pathways in the
intestine, for example, in the regulation of intestinal motility through binding of 5-HTR₄ on myenteric cholinergic neurons (Figure 2). Cholinergic regulation of intestinal epithelial cell proliferation is an active area of investigation, with data linking muscarinic acetylcholine receptor activation to colon cancer proliferation and intestinal stem cell division. Recent work by Greig et al showed that stimulation of the muscarinic acetylcholine receptor M1 subtype leads to increased mucosal surface area and enterocyte proliferation in mice, similar to the effects seen with serotonin potentiation. Furthermore, the M1 receptor is localized to the stem cell niche in the intestinal crypt base. These findings, together with evidence that treatment with prucalopride, a pharmacologic 5-HTR₄ agonist, increased small intestine morphometric and proliferative markers in mice, suggest that serotonin signaling causes intestinal epithelial cell proliferation both directly and via a cholinergic pathway.

The activity of 5-HTR₄ on other cell types supports its role in intestinal epithelial proliferation. For example, 5-HTR₄ on enteric neurons is implicated in neurogenesis through a pathway by which intracellular cyclic adenosine monophosphate production activates proteins involved in cellular proliferation—namely protein kinase A and the extracellular-signal regulated kinase pathway. These same pathways are activated by 5-HTR₄ activation in non-neuronal cell types including human mesangial kidney cells and ovarian tissue.

There is evidence that the 5-HTR₂ family, which has been linked to mitogen-activated protein kinase (MAPK)-mediated cellular proliferation in mouse fibroblasts, also participates in mitogenic signaling in the intestinal epithelium. 5-HTR₂A is expressed in the intestinal mucosa and submucosal plexus, and the proliferative effects of serotonin potentiation are absent when SERT knock-out mice are treated concomitantly with ketanserin, a selective 5-HT₂A antagonist.

Serotonin-Mediated Mitogenic Pathways in Extraintestinal Tissues

To understand the potentially important intracellular pathways in serotonin-induced mitogenesis, it is useful to examine the role of 5-HT in pathologic cellular proliferation and induction of cellular division in nonproliferating cells (Figure 3). Nemecek et al described evidence of serotonin acting as a mitogen in their study of vascular remodeling. They determined that cellular division of bovine smooth muscle cells was enhanced by exposure to serotonin and platelet-derived growth factor stored within platelets. Further research linked idiopathic pulmonary hypertension to abnormal serotonin release from platelets and the extracellular-signal regulated kinase pathway. These same pathways are activated by 5-HTR₄ activation in non-neuronal cell types including human mesangial kidney cells and ovarian tissue.
addition, 5-HTR and SERT activity have been implicated in the up-regulation of mitogenic pathways and DNA replication in pulmonary artery smooth muscle cells.81,85,87
Later, Balasubramanian and Palouse88 shed light on how serotonin induces differentiated hepatocytes to re-enter the cell cycle. Unlike fibroblasts in vascular endothelium and smooth muscle, hepatocytes typically are nonproliferating cells that can be induced to undergo cell division under specific conditions—namely, after a partial liver resection. Thus, the investigation of 5-HT-mediated hepatocyte division paved the way for understanding how serotonin signaling facilitates bypass of cell-cycle checkpoints. Balasubramanian and Palouse48 observed increased binding of 5-HTRs during hepatocyte regeneration, and found that 5-HTR2 activation was associated specifically with downstream activation of protein kinase C, an established intracellular messenger for cell growth and division. The 5-HTR2A subtype subsequently was identified as the specific receptor activated during liver regeneration, drawing a parallel between what is known about 5-HT signaling during proliferation of hepatocytes and intestinal epithelial cells.48

TPH1 knockout mice show impaired liver regeneration after heptectomy, further supporting the mitogenic role of 5-HT, and implicating non-neuronal sources of serotonin in this process.4,89 However, CNS regulation also appears to play a role in this process, with data showing that autonomic nervous system activation of EC cells after partial heptectomy increases peripheral 5-HT production and corresponding 5-HTR activation in regenerating hepatocytes.70

Serotonin-Mediated Neurogenesis and Neuroprotection in the ENS

Serotonin reuptake inhibitor (SSRI)-mediated neurogenesis underlies the effectiveness of this drug class as an antidepressant, and has contributed to understanding of 5-HT as a regulator of cellular proliferation in both the CNS and ENS.91–93

The ENS is derived from vagal- and sacral-level neural crest cells that migrate to and within the gut of the developing embryo, as well as from Schwann cells, which adopt a neuronal fate in the postnatal period.94,95 5-HT signaling contributes to the development of the ENS, as evidenced by decreased myenteric neuronal density in TPH1 knockout mice compared with wild type.50 Furthermore, the specific development of neurons responsive to the neurotransmitters dopamine and \( \gamma \)-aminobutyric acid in the ENS, is sensitive to serotonin signaling.50

Serotonin signaling is critical during embryonic development outside of the nervous system as well. Various 5-HTR subtypes are expressed differentially throughout mouse embryogenesis, and appear to regulate the rate of cellular division and cleavage of the early embryo. Specifically, 5-HTR2 binding and downstream signaling have been studied in detail and are necessary for normal myocardial development and neural crest differentiation.96–98 The role of serotonin signaling in intestinal epithelial development has not been well studied, although EC cells and 5-HT production are detected within the mouse intestinal epithelium as early as embryonic day 16.99

Although the ganglia that comprise the ENS are present and functional at birth, the intricate enteric neural circuitry continues to develop and mature throughout adult life.100–103 Serotonergic signaling plays an important role in this maturation. Much of what we know about 5-HT-mediated cellular proliferation in the ENS comes from recent work by Liu et al,67 who studied neurogenesis in 5-HTR4 knockout mice. As discussed earlier, 5-HTR4 has an established role in gut motility and neurogenesis. Liu et al67 found that wild-type mice treated with 5-HTR4 agonists formed new neurons in the muscular layers of the small intestine that proceeded to migrate into the myenteric plexus; conversely, these newly generated neurons were absent when 5-HTR4 knockout mice were treated with 5-HTR4 agonists. Subsequent studies have recapitulated these findings and showed that 5-HT plays a neuroprotective role, with
the capacity for 5-HTR4 activation to induce enteric neurogenesis after insults to the intestine.\textsuperscript{104–107}

**Serotonin and Proliferation of Cancer Cells**

Serotonin-mediated induction of the cell cycle regulates physiologic cell division in the setting of the intestinal crypt cell, and a beneficial adaptive response in the setting of hepaticoyte regeneration after liver resection. At the molecular level, these intracellular pathways are not far removed from those activated in cancer cells to facilitate evasion of cell-cycle checkpoints. Since Tutton and Barkla’s\textsuperscript{57} discovery of serotonergic regulation of colorectal adenocarcinoma, our understanding of the role of 5-HT in intestinal stem cell proliferation and the pathogenesis of colonic neoplasia has grown substantially. Colorectal adenocarcinoma tumor specimens show 5-HTR overexpression when compared with normal colon tissue, specifically of the 5-HT\textsubscript{1D}, 5-HTR\textsubscript{4C} and 5-HTR\textsubscript{4R}-receptor subtypes.\textsuperscript{108} Serotonin-receptor binding has been linked to colorectal tumor angiogenesis, invasion, and migration in experimental models, correlating with data that circulating plasma serotonin levels are higher in colon cancer patients, and are associated with worse cancer prognosis.\textsuperscript{108–110} Recent research by Sakita et al\textsuperscript{111} further elucidated the role of 5-HT signaling in colorectal carcinogenesis by showing that colonocytes in TPH1 knockout animals show more DNA damage and worse intestinal inflammation than wild-type animals—both of which are etiologic precursors to colon cancer.

Despite this evidence linking 5-HTR activation to cancer progression, SSRI use has been associated with a decreased risk of colorectal cancer, both in a large database analysis of human beings and in rodent models.\textsuperscript{112,113} In the face of these seemingly contradictory data, study of serotonin’s role in the pathogenesis of other tumors supports the link between serotonin signaling and neoplasia. In a review of genomic data from multiple cancer cell lines, Ballou et al\textsuperscript{114} found that cancer cells showed clear gene overexpression of specific 5-HTR subtypes, with similarities seen among diverse cell lines that shared a tumor origin. Furthermore, they found that inhibition of serotonin signaling may have therapeutic benefit. In experimental models of breast cancer and sarcoma, pharmacologic inhibition with a variety of 5-HTR antagonists, with the exception of antagonists to the 5-HTR\textsubscript{3} family, resulted in reduced phosphorylation of cancer signaling molecules including Protein Kinase B, MAP kinases, and cyclin-dependent kinases, along with a reduction in tumor cell viability.\textsuperscript{114}

Importantly, serotonin potentiation has been linked to downstream activation of proliferative cellular pathways in non–colorectal cancer types. In human osteosarcoma cells, 5-HT exposure was associated with increased phosphorylation of p38 and p42 MAP kinases, which regulates expression of a number of transcription factors involved in cellular proliferation.\textsuperscript{114,115} In prostate cancer cells, the MAP kinase/extracellular–signal regulated kinase and phosphoinositide-3 kinase/Protein Kinase B cellular pathways are up-regulated by activation of the 5-HT\textsubscript{1A} receptor, facilitating cancer cell proliferation and migration.\textsuperscript{116}

**Therapeutic Considerations**

Intestinal injury from inflammatory and ischemic disease and malabsorptive states in the setting of short-bowel syndrome pose a challenge to clinicians given the chronic nature of these conditions and the limitations of intestinal replacement therapies.\textsuperscript{7} Exploiting the mitogenic properties of serotonin offers a promising therapeutic approach to these difficult clinical problems. Fortunately, the agents that have enabled detailed study of the downstream effects of 5-HT signaling, namely SSRIs and 5-HTR agonists and antagonists, also are viable pharmacologic therapies. Citalopram, an SSRI, and prucalopride, a 5-HTR\textsubscript{4} agonist, have been shown to increase mucosal surface area and the absorptive capacity of the intestinal epithelium in mouse models.\textsuperscript{38,60,62} In addition, citalopram treatment confers a protective effect to the intestinal epithelium in a mouse model of intestinal ischemia, with enhanced enterocyte renewal.\textsuperscript{64}

As mentioned previously, SSRI use has not been associated with increased rates of intestinal neoplasia, despite the evidence linking serotonin potentiation to enterocyte proliferation and colorectal cancer pathogenesis, and has in fact been shown to have therapeutic potential in reducing tumor viability in other malignancies.\textsuperscript{109,110,114} This is reassuring for the therapeutic application of SSRIs to conditions of intestinal insufficiency, particularly when glucagon-like peptide 2 agonists, an alternate investigational treatment for this indication, carry risks of carcinogenesis.\textsuperscript{117}

Indeed, as a class of drugs, SSRIs show a relatively benign side-effect and risk profile, despite the ubiquity of 5-HT and SERT in the body. When used for CNS indications, common off-target effects include GI symptoms and sexual dysfunction.\textsuperscript{116,119} Although further research is needed to determine optimal dosing and administration of SSRIs for therapeutic use in intestinal insufficiency, and to characterize adverse off-target effects, current evidence suggests that the harm of long-term SSRI use is minimal.

**Conclusions**

A critical element of 5-HT signaling is its ability to exert long-term changes on cell fate and gene expression, as evidenced by its mitogenic effect on the intestinal mucosa and enteric nervous system. 5-HTR binding on diverse cell types, including intestinal stem cells, activates intracellular pathways that lead to cellular proliferation and mitogenesis. Division of undifferentiated stem cells and transit-amplifying cells in the intestinal crypt is mediated by serotonergic signaling in the ENS. This effect is observed in normal, injured, and neoplastic cells, and evidently is mediated through cholinergic pathways, as well as through direct binding of 5-HTRs on mucosal cells. Furthermore, serotonin is essential for neurogenesis and continued regeneration of the enteric neurons throughout life, underscoring the importance of serotonergic neurotransmission in GI function. SSRIs and 5-HTR binding agents hold promise as therapies to harness the translational potential of
serotonin-mediated proliferation for conditions of intestinal injury or insufficiency. Modification of 5-HT signaling is already within the means of medicine, given the established arsenal of SERT inhibitors and 5-HTR antagonists that exist, but additional research is warranted to characterize the risks and benefits to patients with intestinal insufficiency in the clinical setting.

References

1. Tsukamoto K, Ariga H, Mantyh C, Pappas TN, Yanagi H, Yamamura T, Takahashi T. Luminally released serotonin stimulates colonic motility and accelerates colonic transit in rats. Am J Physiol Regul Integr Comp Physiol 2007;293:64–69.

2. Guseva D, Holst K, Kaune B, Meier M, Keubler L, Glage S, Buettner M, Bleich A, Pabst O, Bachmann O, Ponimaskin EG. Serotonin 5-HT7 receptor is critically involved in acute and chronic inflammation of the gastrointestinal tract. Inflamm Bowel Dis 2014;20:1516–1529.

3. Nemecek GM, Coughlin SR, Handley DA, Moskowitz MA. Stimulation of aortic smooth muscle cell mitogenesis by serotonin. Proc Natl Acad Sci U S A 1986;83:674–678.

4. Lesurtel M, Graf R, Aleil B, Walther DJ, Tian Y, Jochum W, Gachet C, Bader M, Clavien PA. Platelet-derivered serotonin mediates liver regeneration. Science 2006;312:104–107.

5. Gross ER, Gershon MD, Margolis KG, Gertsberg ZV, Li Z, Cowles RA. Neuronal serotonin regulates growth of the intestinal mucosa in mice. Gastroenterology 2012;143:408–417.e2.

6. Fishbein TM, Matsumoto CS. Intestinal replacement therapy: timing and indications for referral of patients to an intestinal rehabilitation and transplant program. Gastroenterology 2006;130:S147–S151.

7. Ludwig C, Schmidt A. Das Verhalten der Gase, welche mit dem Blutdurch den reizbaren Saugethermuskul strömen. Berichte über die Verhandlungen der Königlich Sächsischen Gesellschaft der Wissen-schaften zu Leipzig. 1868;20:12–72.

8. Trendelenburg P. Bestimmung des Adrenalingehaltes im normalen Blut sowie beim Abklingen der Wirkung einer einmaligen intravenösen Adrenalininjektion mittels physiologischer Messmethode. Arch Exp Pathol Pharmakol 1910;63:161–176.

9. O’Connor JM. Über den Adrenalingehalt des Blutes. Arch Exp Pathol Pharmakol 1912;67:195–232.

10. Janeway TC, Richardson HB, Park EA. Experiments on the vasoconstrictor action of blood serum. Arch Intern Med 1918;21:565–603.

11. Rapport MM, Green AA, Page IH. Serum vasoconstrictor (serotonin). J Biol Chem 1949;176:1243–1251.

12. Erspamer V, Asero B. Identification of enternamine, the specific hormone of the enterochromaffin cell system, as 5-hydroxytryptamine. Nature 1952;169:800–801.

13. Vialli M, Erspamer V. Caratteristiche istochimiche delle cellule enterocromaffini. Boll Soc Ital Biol Sper 1933;8:885–887.

14. Welsh JH. Excitation of the heart of Venus mercenaria. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 1953;219:23–29.

15. Twarog BM, Page IH. Serotonin content of some mammalian tissues and urine and a method for its determination. Am J Physiol 1953;175:157–161.

16. Carneiro AMD, Cook EH, Murphy DL, Blakely RD. Interactions between integral alphallbbeta3 and the serotonin transporter regulate serotonin transport and platelet aggregation in mice and humans. J Clin Invest 2008;118:1544–1552.

17. Kaumann AJ, Levy FO. 5-hydroxytryptamine receptors in the human cardiovascular system. Pharmacol Ther 2006;111:674–708.

18. Warden SJ, Robling AG, Sanders MS, Blizziotes MM, Turner CH. Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology 2005;146:685–693.

19. Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007;132:397–414.

20. Ichiyama A, Nakamura S, Nishizuka Y, Hayashi O. Enzymic studies on the biosynthesis of serotonin in mammalian brain. J Biol Chem 1970;245:1699–1709.

21. Walther DJ, Peter JU, Bashammakh S, Hörtmagi H, Voits M, Fink H, Bader M. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 2003;299:76.

22. Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 1991;12:151–180.

23. Pelosi B, Pratelli M, Migliarini S, Pacini G, Pasqualetti M. Generation of a Tph2 conditional knockout mouse line for time- and tissue-specific depletion of brain serotonin. PLoS One 2015;10:e0136422.

24. Côte F, Thévenot E, Fligny C, Fromes Y, Darmon M, Ripoche MA, Bayard E, Hanoun N, Saurini F, Lechat P, Dandolo L, Hamon M, Mallet J, Vojdani G. Disruption of the nonneuronal tph1 gene demonstrates the importance of peripheral serotonin in cardiac function. Proc Natl Acad Sci U S A 2003;100:13525–13530.

25. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PP. International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994;46:157–203.

26. Filip M, Bader M. Overview on 5-HT receptors and their role in physiology and pathology of the central nervous system. Pharmacol Rep 2009;61:761–777.

27. Ramsay RR, Albreht A. Kinetics, mechanism, and inhibition of monoamine oxidase. J Neural Transm 2018;125:1659–1683.

28. Gershon MD, Drakontides AB, Ross LL. Serotonin: synthesis and release from the myenteric plexus of the mouse intestine. Science 1965;149:197–200.

29. Gershon MD. 5-Hydroxytryptamine (serotonin) in the gastrointestinal tract. Curr Opin Endocrinol Diabetes Obes 2013;20:14–21.

30. Keszthelyi D, Troost FJ, Masclee AAM. Understanding the role of tryptophan and serotonin metabolism in...
gastrointestinal function. Neurogastroenterol Motil 2009; 21:1239–1249.
31. Sjölund K, Sandén G, Hákanson R, Sundler F. Endocrine cells in human intestine: an immunocytochemical study. Gastroenterology 1983;85:1120–1130.
32. Beumer J, Artegiani B, Post Y, Reimann F, Gribble F, Nguyen TN, Zeng H, Van den Born M, Van Es JH, Clevers H. Enterendocrine cells switch hormone expression along the crypt-to-villus BMP signalling gradient. Nat Cell Biol 2018;20:909–916.
33. Habib AM, Richards P, Caims LS, Rogers GJ, Wheatcroft J, Wakelin D, Smith A, Mahoney CR, Wade PR, Tamir H, Kirchgessner AL, Gershon MD.
34. Habib AM, Richards P, Caims LS, Rogers GJ.
35. Mawe GM, Hoffman JM. Serotonin signalling in the gut. Mucosal Immunol 2013;6:146–152.
36. Mawe GM, Hoffman JM. Serotonin signalling in the gut. Mucosal Immunol 2013;6:146–152.
37. Fiorica-Howells E, Hen R, Gingrich J, Li Z, Gershon MD.
38. Fiorica-Howells E, Hen R, Gingrich J, Li Z, Gershon MD.
39. Reimann F, Gribble FM. Overlap of endocrine hormone expression in the mouse intestine revealed by transcripional profiling and flow cytometry. Endocrinology 2012;153:3054–3065.
40. Wade PR, Tamir H, Kirchgessner AL, Gershon MD. Analysis of the role of 5-HT in the enteric nervous system using anti-idiotype antibodies to 5-HT receptors. Am J Physiol Gastrointest Liver Physiol 1994;266:G403–G416.
41. Wade PR, Tamir H, Kirchgessner AL, Gershon MD.
42. Hoffman JM, Tyler K, Maceachern SJ, Balemba OB, Bannon CAM, Parker HE, Morley TCE, Yeo GSH, Zambrowicz B, Jhaver KG, Diacou A, Gershon MD. Pharmacological reduction of mucosal but not neuronal serotonin opposes inflammation in mouse intestine. Gut 2014;63:928–937.
43. Ghia JE, Li N, Wang H, Collins M, Deng Y, El-Sharkawy RT, Côté F, Mallet J, Khan WI. Serotonin has a key role in pathogenesis of experimental colitis. Gastroenterology 2009;137:1649–1660.
44. Shajib MS, Wang H, Kim JJ, Sunjic I, Ghia JE, Denou E, Collins M, Denburg JA, Khan WI. Interleukin 13 and serotonin: linking the immune and endocrine systems in murine models of intestinal inflammation. PLoS One 2013;8:e72774.
45. Kim JJ, Bridle BW, Ghia JE, Wang H, Syed SN, Manocha MM, Rengasamy P, Shajib MS, Wan Y, Hedlund PB, Khan WI. Targeted inhibition of serotonin type 7 (5-HT7) receptor function modulates immune responses and reduces the severity of intestinal inflammation. J Immunol 2013;190:4795–4804.
46. Yin J, Albert RH, Tretiakova AP, Jameson BA. 5-HT(1B) receptors play a prominent role in the proliferation of T lymphocytes. J Neuroimmunol 2006;181:68–81.
47. Li Z, Chalazonitis A, Huang YY, Mann JJ, Margolis KG, Yang QM, Kim DO, Côté F, Mallet J, Gershon MD. Essential roles of enteric neuronal serotonin in gastrointestinal motility and the development/survival of enteric dopaminergic neurons. J Neurosci 2011;31:8998–9009.
48. Chen JJ, Li Z, Pan H, Murphy DL, Tamir H, Koepsell H, Gershon MD. Maintenance of serotonin in the intestinal mucosa and ganglia of mice that lack the high-affinity serotonin transporter: abnormal intestinal motility and the expression of cation transporters. J Neurosci 2001;21:6348–6361.
49. Kulke MH, DorisIO TO, Phan A, Bergsland E, Law L, Banks P, Freiman J, Frazier K, Jackson J, Yao JC, Lapuerta P, Zambrowicz B, Fleming D, Sands A, Telo-tristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. Endocr Relat Cancer 2015;21:705–714.
50. Bernpwd PP, Kunze WAA, Furness JB, Boyntone JC. The terminals of myenteric intrinsic primary afferent neurons of the guinea-pig ileum are excited by 5-hydroxytryptamine acting at 5-hydroxytryptamine-3 receptors. Neuroscience 2000;101:459–469.
51. Terry N, Margolis KG. Serotonergic mechanisms regulating the GI tract: experimental evidence and
therapeutic relevance. Handb Exp Pharmacol 2017; 239:319–342.
55. Cunningham D, Hawthorn J, Pople A, et al. Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5HT3 receptor antagonist. Lancet 1987; 1:461–1463.
56. Gan TJ. Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting are they all the same? 2005; 19:225–238.
57. Tutton PJM, Barkla DH. The influence of serotonin on the mitotic rate in the colonic crypt epithelium and in colonic adenocarcinoma in rats. Clin Exp Pharmacol Physiol 1978; 5:91–94.
58. Bullen TF, Forrest S, Campbell F, Dodson AR, Hershman MJ, Pritchard DM, Turner JR, Montrose MH, Watson AJM. Characterization of epithelial cell shedding from human small intestine. Lab Invest 2006; 86:1052–1063.
59. Tappenden KA. Pathophysiology of short bowel syndrome: considerations of resected and residual anatomy. JPEN J Parenter Enteral Nutr 2014; 38:14S–22S.
60. Zhang L, Greig CJ, Cowles RA. Orally dosed citalopram stimulates small intestinal mucosal growth. J Surg Res 2019; 236:326–331.
61. Tackett JJ, Gandotra N, Bamdad MC, Muiue ED, Cowles RA. Enhanced serotonin signaling stimulates ordered intestinal mucosal growth. J Surg Res 2016; 208:198–203.
62. Park CJ, Armenia SJ, Shaughnessy MP, Greig CJ, Cowles RA. Potentiation of serotonin signaling leads to increased carbohydrate and lipid absorption in the murine small intestine. J Pediatr Surg 2019; 54:1245–1249.
63. Greig CJ, Zhang L, Cowles RA. Potentiated serotonin signaling in serotonin re-uptake transporter knockout mice increases enterocyte mass and small intestinal absorptive function. Physiol Rep 2019; 7:e14278.
64. Tackett JJ, Gandotra N, Bamdad MC, Muiue ED, Cowles RA. Potentiation of serotonin signaling protects against intestinal ischemia and reperfusion injury in mice. Neurogastroenterol Motil 2019; 31:e13498.
65. Coates MD, Mahoney CR, Linden DR, Sampson JE, Chen J, Blaszyl H, Crowell MD, Sharkey KA, Gershon MD, Mauve GM, Moses PL. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004; 126:1657–1664.
66. Gershon MD. 5-HT 4-mediated neuroprotection: a new therapeutic modality on the way? Am J Physiol Liver Physiol 2020; 100:327–676.
67. Liu MT, Kuan YH, Wang J, Hen R, Gershon MD. 5-HT4 receptor-mediated neuroprotection and neurogenesis in the enteric nervous system of adult mice. J Neurosci 2009; 29:9683–9699.
68. Takaki M, Goto K, Kawahara I. The 5-hydroxytryptamine 4 receptor agonist-induced actions and enteric neurogenesis in the gut. J Neurogastroenterol Motil 2014; 20:17–30.
69. Stakenborg N, Labeuw E, Gomez-Pinilla PJ, Schepper SD, Aerts R, Goverse G, Farro G, Appelants I, Meroni E, Stakenborg M, Viola MF, Gonzalez-Dominguez E, Bosmans G, Alpizar YA, Woltius A, Hoore AD, Van Beek K, Verheijden S, Verhaegen M, Derue R, Waelkens E, Moretti M, Gotti C, Augustinps J, Talavera K, Berghe PV, Matteoli G, Boecxkstaens GE. Preoperative administration of the 5-HT4 receptor agonist prucalopride reduces intestinal inflammation and shortens postoperative ileus via cholinergic enteric neurons. Gut 2019; 68:1406–1416.
70. Pauwelyn V, Lefebvre RA. 5-HT(4) receptors facilitate cholinergic neurotransmission throughout the murine gastrointestinal tract. Neurogastroenter Molit 2017; 29.
71. Frucht H, Jensen RT, Dexter D, Yang W. Human colon cancer cell proliferation mediated by the M 3 muscarinic cholinergic receptor. Clin Cancer Res 1999; 5:2532–2539.
72. Lundgren O, Jodal M, Jansson M, Ryberg AT, Svensson L. Intestinal epithelial stem/progenitor cells are controlled by mucosal afferent nerves. PLoS One 2011; 6:e16295.
73. Ukegawa J, Takeuchi Y, Kusayanagi S, Mitamura K. Growth-promoting effect of muscarinic acetylcholine receptors in colon cancer cells. J Cancer Res Clin Oncol 2003; 129:272–278.
74. Greig CJ, Cowles RA. Muscarinic acetylcholine receptors participate in small intestinal mucosal homeostasis. J Pediatr Surg 2017; 52:1031–1034.
75. Greig CJ, Armenia SJ, Cowles RA. The M1 muscarinic acetylcholine receptor in the crypt stem cell compartment mediates intestinal mucosal growth. Exp Biol Med (Maywood) 2020; 245:1194–1199.
76. Barthet G, Framery B, Gaven F, Pellissier L, Reiter E, Claesen S, Dumuis A. 5-Hydroxytryptamine 4 receptor activation of the extracellular signal-regulated kinase pathway depends on src activation but not on G protein or beta-arrestin signaling. Mol Biol Cell 2007; 18:1979–1991.
77. Henriksen R, Dizey N, Abrahamsson PA. Expression of serotonin receptors 5-HT1A, 5-HT1B, 5-HT2B and 5-HT4 in ovary and in ovarian tumours. Anticancer Res 2012; 32:1361–1366.
78. Norum JH, Hart K, Levy FO. Ras-dependent ERK activation by the human Gs-coupled serotonin receptors 5-HT4(b) and 5-HT7(a). J Biol Chem 2003; 278:3098–3104.
79. Nebigil CG, Launay JM, Hickel P, Tournois C, Maroteaux L. 5-hydroxytryptamine 2B receptor regulates cell-cycle progression: cross-talk with tyrosine kinase pathways. Proc Natl Acad Sci U S A 2000; 97:2591–2596.
80. Launay JM, Biriaux G, Bondoux D, Callebert J, Choi DS, Loric S, Maroteaux L. Ras involvement in signal transduction by the serotonin 5-HT2B receptor. J Biol Chem 1996; 271:3141–3147.
81. Welsh DJ, Harnett M, MacLean M, Peacock AJ. Proliferation and signaling in fibroblasts: role of 5-hydroxytryptamine2a receptor and transporter. Am J Respir Crit Care Med 2004; 170:252–259.
82. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M,
83. Chen C, Han X, Fan F, Liu Y, Wang T, Wang J, Hu P, Ma A, Tian H. Serotonin drives the activation of pulmonary artery adventitial fibroblasts and TGF-β1/Smad3-mediated fibrotic responses through 5-HT2A receptors. Mol Cell Biochem 2014;397:267–276.

84. Morecroft I, Dempsey J, Bader M, Walther DJ, Kotnik K, Loughlin L, Nilsen M, MacLean MR. Effect of tryptophan hydroxylase 1 deficiency on the development of hypoxia-induced pulmonary hypertension. Hypertension 2007;49:232–236.

85. Liu Y, Tian HY, Yan XL, Fan FL, Wang WP, Han JL, Zhang JB, Ma Q, Meng Y, Wei F. Serotonin inhibits apoptosis of pulmonary artery smooth muscle cell by pERK1/2 and PDK through 5-HT1B receptors and 5-HT transporters. Cardiovasc Pathol 2013;22:451–457.

86. Pakala R, Willerson JT, Benedict CR. Mitogen effect of serotonin on vascular endothelial cells. Circulation 1994;90:1919–1926.

87. Eddahibi S, Humbert M, Fadel E, Raffestin B, Darmon M, Capron F, Simonneau G, Darvelle P, Hamon M, Adnot S. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 2001;108:1141–1150.

88. Balasubramanian S, Paulose CS. Induction of DNA synthesis in primary cultures of rat hepatocytes by serotonin: possible involvement of serotonin S2 receptor. Hepatology 1998;27:62–66.

90. Nocito A, Georgiev P, Dahm F, Jochum W, Bader M, Graf R, Clavien PA. Platelets and platelet-derived serotonin promote tissue repair after normothermic hepatic ischemia in mice. Hepatology 2007;45:369–376.

91. Inoue R, Kamimura K, Nagoya T, Sakai N, Yokoo T, Goto R, Ogawa K, Shinagawa-Kobayashi Y, Watanabe-Mori Y, Sakamaki A, Abe S, Kamimura H, Miyamura N, Nishina H, Terai S. Effect of a neural relay on liver regeneration in mice: activation of serotonin release from the gastrointestinal tract. FEBS Open Bio 2018;8:449–460.

92. Segi-Nishida E. The effect of serotonin-targeting antidepressants on neurogenesis and neuronal maturation of the hippocampus mediated via 5-HT1A and 5-HT4 receptors. Front Cell Neurosci 2017;11:142.

93. Wang J-W, David DJ, Moncikton JE, Battaglia F, Hen R. Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. J Neurosci 2008;28:1374–1384.

94. Young HM, Hearn CJ, Newgreen DF. Embryology and development of the enteric nervous system. Gut 2000;47:12–14.

95. Uesaka T, Nagashimada M, Enomoto H. Neuronal differentiation in Schwann cell lineage underlies postnatal neurogenesis in the enteric nervous system. J Neurosci 2015;35:9879–9888.

96. Lauder JM, Wilkie MB, Wu C, Singh S. Expression of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors in the mouse embryo. Int J Dev Neurosci 2000;18:653–662.

97. Buznikov GA, Lambert WH, Lauder JM. Serotonin and serotonin-like substances as regulators of early embryogenesis and morphogenesis. Cell Tissue Res 2001;305:177–186.

98. Choi DS, Ward SJ, Messaddeq N, Launay JM, Maroteaux L. 5-HT2B receptor-mediated serotonin morphogenetic functions in mouse cranial neural crest and myocardial cells. Development 1997;124:1745–1755.

99. Branchek TA, Gershon MD. Time course of expression of neuropeptide Y, calcitonin gene-related peptide, and NADPH diaphorase activity in neurons of the developing murine bowel and the appearance of 5-hydroxytryptamine in mucosal enterochromaffin cells. J Comp Neurol 1989;285:262–273.

100. Pham TD, Gershon MD, Rothman TP. Time of origin of neurons in the murine enteric nervous system: sequence in relation to phenotype. J Comp Neurol 1991;314, 798–798.

101. Fiorica-Howells E, Maroteaux L, Gershon MD. Serotonin and the 5-HT 2B receptor in the development of enteric neurons. J Neurosci 2000;20:294–305.

102. Kruger GM, Mosher JT, Bixby S, Joseph N, Iwashita T, Morrison SJ. Neural crest stem cells persist in the adult gut but undergo changes in self-renewal, neuronal subtype potential, and factor responsiveness. Neuron 2002;35:657–669.

103. Kulkarni S, Micca MA, Leser J, Shin C, Tang SC, Fu YY, Liu L, Li Q, Saha M, Li C, Enikolopov G, Becker L, Rakhlin N, Anderson M, Shen X, Dong X, Butte MJ, Song H, Southard-Smith EM, Kapur RP, Bogunovic M, Pasricha PJ. Adult enteric nervous system in health is maintained by a dynamic balance between neuronal apoptosis and neurogenesis. Proc Natl Acad Sci U S A 2017;114:E3709–E3718.

104. Gershon MD. Serotonin is a sword and a shield of the bowel: serotonin plays offense and defense. Trans Am Clin Climatol Assoc 2012;123:268–280.

105. Bianco F, Bonora E, Natarajan D, Vargiolu M, Thapar N, Torresan F, Giancola F, Boschetti E, Volta U, Bazzoli F, Mazzoni M, Seri M, Clavennazi P, Stanghellini V, Sternini C, De Giorgio R. Prucalopride exerts neuroprotection in human enteric neurons. Am J Physiol Gastrointest Liver Physiol 2016;310:G768–G775.

106. Takaki M, Goto K, Kawahara I, Nabejaka J. Activation of 5-HT4 receptors facilitates neurogenesis of injured enteric neurons at an anastomosis in the lower gut. J Smooth Muscle Res 2015;51:82–94.

107. Matsuyoshi H, Kuniyasu H, Okumura M, Misawa H, Katsui R, Obata K, Takaki M. A 5-HT 4-receptor activation-induced neural plasticity enhances in vivo reconstructs of enteric nerve circuit insult. Neurogastroenterol Motil 2010;22:806–814.
(5-HT1DR) promotes colorectal cancer metastasis by regulating axin 1/β-catenin/MMP-7 signaling pathway. Oncotarget 2015;6:25975–25987.

109. Xia Y, Wang D, Zhang N, Wang Z, Pang L. Plasma serotonin level is a predictor for recurrence and poor prognosis in colorectal cancer patients. J Clin Lab Anal 2018;32:1–8.

110. Nocito A, Dahm F, Joehum W, Jae HJ, Georgiev P, Bader M, Graf R, Clavien PA. Serotonin regulates macrophage-mediated angiogenesis in a mouse model of colon cancer allografts. Cancer Res 2008;68:5152–5158.

111. Sakita JY, Bader M, Santos ES, Garcia SB, Minto SB, Alenina N, Brunaldi MO, Carvalho MC, Vidotto T, Gasparotto B, Martins RB, Silva WA, Brandão ML, Leite CA, Cunha FQ, Karsenty G, Squire JA, Uyemura SA, Kannen V. Serotonin synthesis protects the mouse colonic crypt from DNA damage and colorectal tumorigenesis. J Pathol 2019;249:102–113.

112. Chubak J, Boudreau DM, Rulyak SJ, Mandelson MT. Colorectal cancer risk in relation to antidepressant medication use. Int J Cancer 2011;128:227–232.

113. Kannen V, Marini T, Turatti A, Carvalho MC, Brandão ML, Jabor VAP, Bonato PS, Ferreira FR, Zanette DL, Silva WA, Garcia SB. Fluoxetine induces preventive and complex effects against colon cancer development in epithelial and stromal areas in rats. Toxicol Lett 2011;204:134–140.

114. Ballou Y, Rivas A, Belmont A, Patel L, Amaya C, Lipson S, Khayou T, Dickerson E, Nahleh Z, Bryan B. 5-HT serotonin receptors modulate mitogenic signaling and impact tumor cell viability. Mol Clin Oncol 2018;243–254.

115. Zhang W, Liu HT. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res 2002;12:9–18.

116. Dizeyi N, Hedlund P, Bjartell A, Tinzl M, Austlid Taskén K, Abrahamsson PA. Serotonin activates MAP kinase and PI3K/Akt signaling pathways in prostate cancer cell lines. Urol Oncol Semin Orig Investig 2011;29:436–445.

117. Thulesen J, Hartmann B, Hare KJ, Kissow H, Orskov C, Holst JJ, Poulsen SS. Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice. Gut 2004;53:1145–1150.

118. James A, Ryan J, Parkman H. Effects of the selective serotonin reuptake inhibitor, fluoxetine, on regional gastric contractility. Neurogastroenterol Motil 2005;17:76–82.

119. Keller Ashton A, Hamer R, Rosen RC. Serotonin reuptake inhibitor-induced sexual dysfunction and its treatment: a large-scale retrospective study of 596 psychiatric outpatients. J Sex Marital Ther 1997;23:165–175.

Received November 12, 2020. Accepted May 12, 2021.

Correspondence
Address correspondence to: Robert A. Cowles, MD, Division of Pediatric Surgery, Department of Surgery, Yale School of Medicine, 310 Cedar Street FMB 131, New Haven, Connecticut 06511. e-mail: robert.cowles@yale.edu; fax: (203) 785-3820.

Conflicts of interest
The authors disclose no conflicts.

Funding
The work was funded by the Department of Surgery, Yale School of Medicine.